CompletedPhase 4ACTRN12608000251325
alpha lipoic acid in burning mouth syndrome:a randomized double-blind placebo-controlled crossover trial
The effect of alpha lipoic acid in the management of burning mouth syndrome
Sponsor
Fundacao de Amparo a Pesquisa do estado de sao paulo
Enrollment
31 participants
Start Date
Jun 25, 2006
Study Type
Interventional
Conditions
Summary
The purpose of this study was to evaluate the effectiveness of alpha lipoic acid as an alternative in the management of burning mouth syndrome
Eligibility
Sex: Both males and femalesMin Age: 30 Yearss
Inclusion Criteria1
- burning mouth for 6 months or more, absence of oral mucosal lesions, absence of sistemic conditions whose could produce burning mouth
Exclusion Criteria1
- oral burning under 6 months sistemic diseases (anemia and diabetes) oral mucosal diseases, hypossalivation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
therapy with alpha lipoic acid orally, three capsules of 200 mg per day during 30 days
There was a washout period of 20 days
therapy with alpha lipoic acid orally, three capsules of 200 mg per day during 30 days There was a washout period of 20 days
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000251325
Related Trials
MucoLock™ for Treatment of Stomatitis
NCT075060181 location
Reducing Patient Memory Recall in the Burning Mouth Patient Population
NCT058196971 location
Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome
NCT060401901 location
Burning Mouth Syndrome: Symptoms and Management
NCT070165551 location